Informasjon vedrørende etterfølgende tilbudet

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE NOTICE.

Oslo, 18. mars 2013

Det vises til børsmeldingene fra DiaGenic ASA ("Selskapet") den 8. mars 2013 og 11. mars 2013, vedrørende en rettet emisjon av 50 000 000 nye aksjer i Selskapet (den ”Rettede Emisjonen”) og innkalling til ekstraordinær generalforsamling i Selskapet den 2. april 2013 (”EGF”).

Styret i Selskapet har foreslått at EGF vedtar en reparasjonsemisjon med bruttoproveny inntil 7 millioner kroner ved utstedelse av inntil 11 666 666 nye aksjer (det "Etterfølgende Tilbudet"). Eksisterende aksjeeiere i Selskapet per 7. mars 2013, som registrert i aksjeeierregisteret i VPS den 12. mars 2013 (”Registreringsdatoen”), med unntak av aksjeeiere som ble tildelt aksjer i den Rettede Emisjonen, vil tildeles cirka 0,64 omsettelig tegningsrett for hver aksje registrert som eid per Registreringsdatoen. Antall tegningsretter som utstedes til hver aksjeeier vil rundes ned til nærmeste hele tegningsrett. Hver tegningsrett vil gi rett til å tegne og bli tildelt én ny aksje i det Etterfølgende Tilbudet (med de begrensninger som angis nedenfor). Tegningsrettene vil søkes notert på Oslo Børs. Overtegning vil være tillatt. Tegning av nye aksjer uten tegningsretter vil ikke være tillatt.

Aksjeeiere (eller andre personer) som, etter Selskapets vurdering, er hjemhørende i en jurisdiksjon hvor slikt tilbud av aksjer ville være ulovlig eller (for andre jurisdiksjoner enn Norge) ville medføre plikt til prospekt, registrering eller lignende tiltak, vil ikke kunne delta i det Etterfølgende Tilbudet.

Tegningskursen i det Etterfølgende Tilbudet vil være 0,60 kroner per aksje, som er lik tegningskursen i den Rettede Emisjonen. Tegningsperioden i Etterfølgende Tilbudet er ventet å starte 9. april 2013 og avslutte 23. april 2013 kl. 16.30 (norsk tid). Hvis prospektet ikke er godkjent av Finanstilsynet i tide slik at tegningsperioden kan starte 9. april 2013, skal tegningsperioden starte den første handelsdagen på Oslo Børs etter at slik godkjennelse er mottatt og avsluttes to uker deretter.

Det Etterfølgende Tilbudet er betinget av (i) godkjennelse av EGF og (ii) at et prospekt utarbeides i samsvar med verdipapirhandelloven og blir godkjent av Finanstilsynet.

For ytterligere informasjon, vennligst kontakt:

Paul de Potocki, CEO, DiaGenic ASA, Telefon +47 23 24 89 67

Ruben Ekbråten, CFO, DiaGenic ASA, Telefon +47 23 24 89 53

Important Notice

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. The Company's manager is acting exclusively for the Company and no one else, and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the Private Placement, the Subsequent Offering, the contents of this announcement or any of the matters referred to herein. The Private Placement, the Subsequent Offering and the distribution of this announcement and other information in connection with the Private Placement and the Subsequent Offering may be restricted by law in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about, and to observe, any such restrictions. This announcement may not be used for, or in connection with, and does not constitute, any offer of securities for sale in the United States or in any other jurisdiction.

The Private Placement and the Subsequent Offering will not be made in any jurisdiction or in any circumstances in which such offer or solicitation would be unlawful. This announcement is not for distribution, directly or indirectly in or into any jurisdiction in which it is unlawful to make any such offer or solicitation to such person or where prior registration or approval is required for that purpose. No steps have been taken or will be taken relating to the Private Placement or the Subsequent Offering in any jurisdiction outside of Norway in which such steps would be required. Neither the publication and/or delivery of this announcement shall under any circumstances imply that there has been no change in the affairs of the Company or that the information contained herein is correct as of any date subsequent to the earlier of the date hereof and any earlier specified date with respect to such information.

This announcement is not for publication or distribution, directly or indirectly, in the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. The shares of the Company, including the shares to be issued in the Private Placement and the Subsequent Offering, have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to, or for the account of, U.S. persons (as such term is defined in Regulation S under the US Securities Act), except pursuant to an effective registration statement under, or an exemption from the registration requirements of, the US Securities Act. All offers and sales outside the United States will be made in reliance on Regulation S under the US Securities Act. There will be no public offer of securities in the United States.

This announcement does not constitute an offering circular or prospectus in connection with an offering of securities of the Company. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in relevant offering documentation to be distributed and made available by the Company only to qualified persons in certain jurisdictions where an offer may be made (if an offer is made). This announcement does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for, any securities and cannot be relied on for any investment contract or decision.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Om DiaGenic ASA

DiaGenic skaper merverdi for pasienter, partnere og investorer gjennom utvikling av innovative og pasientvennlige in vitro diagnostiske (IVD) produkter for tidlig diagnose av sykdommer. Selskapets proprietære konsept innebærer at en sykdom fremkaller systemiske reaksjoner i blodet unik for sykdommen, og som kan måles ved hjelp av en blodprøve. DiaGenic er verdensledende i å identifisere genekspresjonssignaturer i blod og er fokusert på utvikling av biomarkør baserte IVD produkter innen Alzheimers sykdom. Selskapet beskytter sin teknologi gjennom en omfattende patentportefølje. DiaGenic er et norsk selskap notert på Oslo Børs. For mer informasjon vennligst besøk: www.diagenic.com

Om oss

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange. DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented method is based on identifying disease-specific gene signatures from easily available sample material such as blood. DiaGenic's strategy is to work with research and technology partners to develop a pipeline of assays for commercialisation by major diagnostics companies. Currently DiaGenic’s first two tests for the early detection of breast cancer and Alzheimer’s disease are on track to enter extensive clinical trials during 2007. The company has been awarded substantial development grants as part of the Norwegian Research Council’s FUGE programme.

Abonner